KDM2A and central nervous system cancer: Compared to ALT-positive cells in which ablation of KDM2A by sgK#1 or #2 led to 35−100-fold dropout in a period of 4 weeks, targeting KDM2A by the same sgRNAs incurred <2.5-fold growth inhibition in the panel of non-ALT human cell lines, including IMR90-T (Fig. 2a), HeLa of cervical cancer (Fig. 2b), NCI-H1299 of non-small cell lung carcinoma (Fig. 2c), MG63 of osteosarcoma (Supplementary Fig. 4a), MCF7 of breast cancer (Supplementary Fig. 4b), glioma cell lines A172, LN464, and U118 (Supplementary Fig. 4c–e), and primary lung fibroblast IMR90 cells (Supplementary Fig. 4f).